NICM
FLNA

Neo Ivy Capital Management’s Filana Therapeutics FLNA Stock Holding History

Neo Ivy Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-665
Closed -$57K – 612
2021
Q2 		$57K Buy
+665
New +$35.6K 0.06% 311

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Neo Ivy Capital Management's FLNA Position: Q3 2021 in Review

Neo Ivy Capital Management sold out of Filana Therapeutics (FLNA) in Q3 2021, closing a stake of 665 shares — an estimated $57K sold.

Neo Ivy Capital Management first reported a position in FLNA in Q2 2021 and held it in 1 quarter. The position peaked at $57K in Q2 2021. 180 funds tracked by Wall St. Rank hold FLNA as of Q3 2021.

  • Neo Ivy Capital Management reported no remaining Filana Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Neo Ivy Capital Management sold 665 Filana Therapeutics shares in Q3 2021, an estimated $57K.
  • Neo Ivy Capital Management first reported a position in Filana Therapeutics in Q2 2021 and held it in 1 quarter.
  • Neo Ivy Capital Management's Filana Therapeutics position peaked at $57K in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2021.

Based on Neo Ivy Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.